Abstract Book

S750

ESTRO 37

Results The patient characteristics are listed in the table

Locoregional (LPFS), progression-free survival (PFS), and overall survival (OS) were assessed, and patterns of failure and prognostic factors were evaluated. Results A total of 372 patients were included in the analysis. A median follow-up period was 19 months (range, 2-146 months) and the median age at the time of diagnosis was 62 years (range, 32-83 years). Only 43 patients (12%) was woman and 319 patients (86%) had clinical stage Ⅲ disease. A quarter of patients received sequential CRT, but the others were fitted for concurrent CRT. In concurrent CRT group, radiotherapy started at the 3 rd cycle of chemotherapy in some patients, but the others received concurrent CRT from the beginning. The 5-year LPFS, PFS, and OS were 45%, 23%, and 26%, respectively. A total of 81 patients (22%) experienced local progression as first site of failure, although distant metastasis was more common. For those who received prophylactic cranial irradiation (PCI) (160 patients, 43%), PFS, frequency of brain metastasis, and OS were improved. On multivariate analysis, concurrent CRT, clinical stage, and PCI were statistically significant prognostic factor for OS. Conclusion Concurrent CRT showed better clinical outcomes regardless of the timing of RT than sequential RT. Future investigation for the dose-escalation of in-house radiotherapy dose should be considered. EP-1374 SBRT for new lesions after surgery or curative intended radiotherapy in patients with NSCLC O. Hansen 1,2 , C. Kristiansen 1 , S.S. Jeppesen 1,2 , T.B. Nielsen 3 , T. Schytte 1 , M. Nielsen 3 1 Odense University Hospital, Dept. Oncology, Odense, Denmark 2 Odense University Hospital, Academy of Geriatric Research AgeCare, Odense, Denmark 3 Odense University Hospital, Laboratory of Radiation Physics, Odense, Denmark Purpose or Objective Stereotactic Radiotherapy (SBRT) is an efficient treatment for early stages of inoperable NSCLC, but may also be used when new tumors arise after previously curatively intended by surgery or radiotherapy (RT). The aim of this study was to study the outcome of SBRT in these situations Material and Methods All cases of NSCLC treated with SBRT at our institution are prospectively recorded. From July 2009 to December 2016 137 patients previous treated with curatively intend with either surgery or RT had SBRT for new lesions. The doses used for peripheral located tumors were 45-66 Gy (central doses) in 3 fractions (F) while the doses for centrally located tumors were 45 Gy/10 F, 50 Gy/5 F and 80 Gy/8 F. The SBRT technique was either IMRT or VMAT. 97 patients previously had surgery (S-Grp): Resection 23 (24%), lobectomy 67 (69%), bi-lobectomy 1 (1%), or pneumonectomy 6 (6%). 40 patients had previously RT (RT-Grp): SBRT 25 (62.5%) or conventionally fractionated RT 15 (37.5%). All patients had more than 10 months (mo.) of potential follow-up. Overall survival was calculated from day one in the treatment of the new lesion progression-free survival

The median, 1, 2, 3, and 4 year overall survival was 50.5 mo., 88%, 74%, 61%, and 58 % in the S-Grp and 20.0 mo., 72%, 50%, 42%, and 37% in the RT-Grp, (p=.021)

Conclusion The survival after SBRT for patients previously treated with surgery was better than patients previously treated with RT, but the survival in both groups was very good EP-1375 Pre-radiotherapy quality of live assessment predicts survival in lung cancer patients J.M. Nieto-Guerrero Gómez 1 , J. Cacicedo Fernández de Bobadilla 2 , B.D. Delgado León 1 , D. Herrero Rivera 3 , E. Montero Perea 1 , J.M. Praena Fernández 4 , M.J. Ortiz Gordillo 1 , J.L. López Guerra 1 1 Virgen del Rocío University Hospital, Radiation Oncology, Sevilla, Spain 2 Cruces Hospital, Radiation Oncology, Bilbao, Spain 3 Virgen del Rocío University Hospital, Oncology, Sevilla, Spain 4 Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla, Methodology Unit, Sevilla, Spain Purpose or Objective Lung cancer (LC) has a significant impact on patients' health-related quality of life (HRQOL). We investigate the correlations between pre-radiotherapy HRQOL and survival. Material and Methods We conducted a prospective multicentric study with 437 LC patients that were seen in consultation at radiation oncology departments from 2013 to 2016. Quality of live was assessed using the EORTC-QLQ-C30 (v3.0) questionnaire. Global health status (GHS), physical (PF), role (RF), emotional (EF), cognitive (CF) and social functioning (SF) scores were evaluated. Several patient factors, tumor features and treatments were considered for the analysis. Results The median age was 66 years (range 31-88). The TNM classification was as follows: stage I 12 patients, stage II 16 patients, stage III 351 patients and 58 patients with